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Abstract
Background: Umbilical cord matrix mesenchymal stem cells (UCM-MSCs) present a wide range of potential therapeutical
applications. The extracellular calcium-sensing receptor (CaSR) regulates physiological and pathological processes. We
investigated, in a large animal model, the involvement of CaSR in triggering osteogenic and neurogenic differentiation of
two size-sieved UCM-MSC lines, by using AMG641, a novel potent research calcimimetic acting as CaSR agonist.
Methodology/Principal Findings: Large (.8mm in diameter) and small (,8mm) equine UCM-MSC lines were cultured in
medium with high calcium (Ca2+) concentration ([Ca2+]o; 2.87 mM) and dose-response effects of AMG641 (0.01 to 3mM) on
cell proliferation were evaluated. Both cell lines were then cultured in osteogenic or neurogenic differentiation medium
containing: 1) low [Ca2+]o (0.37 mM); 2) high [Ca
2+]o (2.87 mM); 3) AMG641 (0.05, 0.1 or 1 mM) with high [Ca
2+]o and 4) the
CaSR antagonist NPS2390 (10 mM for 30 min) followed by incubation with AMG641 in high [Ca2+]o. Expression of
osteogenic or neurogenic differentiation biomarkers was compared among groups. In both cell lines, AMG641 dose-
dependently increased cell proliferation (up to P,0.001). Osteogenic molecular markers expression was differentially
regulated by AMG641, with stimulatory (OPN up-regulation) in large or inhibitory (RUNX2 and OPN down-regulation) effects
in small cells, respectively. AMG641 significantly increased alkaline phosphatase activity and calcium phosphate deposition
in both cell lines. Following treatment with AMG641 during osteogenic differentiation, in both cell lines CaSR expression
was inversely related to that of osteogenic markers and inhibition of CaSR by NPS2390 blocked AMG641-dependent
responses. Early-stage neurogenic differentiation was promoted/triggered by AMG641 in both cell lines, as Nestin and CaSR
mRNA transcription up-regulation were observed.
Conclusions/Significance: Calcium- and AMG641-induced CaSR stimulation promoted in vitro proliferation and osteogenic
and early-stage neurogenic differentiation of UCM-MSCs. CaSR activation may play a fundamental role in selecting specific
differentiation checkpoints of these two differentiation routes, as related to cell commitment status.
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Introduction
Recent developments in stem cell biology research area have
revealed that umbilical cord matrix (UCM, also known as
Wharton’s jelly) is a pivotal source of ‘‘young’’ mesenchymal stem
cells (MSCs) considered as much more proliferative, immunosup-
pressive and even more therapeutically active than those from
adult tissue sources [1]. Several groups reported success in
isolating and establishing MSCs cultures from UCM in human
[2–8] as well as in large animal models, such as horses [9–16], pigs
[17,18], and dogs [19–22].
The equine UCM (eUCM) is a well known source of MSCs that
can be easily isolated, cryogenically preserved and in vitro-
differentiated into adipocytes, chondrocytes, osteoblasts and in
cells with a morphology typical of neurons with axon- and
dendrite-like processes [9-12]. Moreover, eUCM-MSCs show
expression of embryonic markers (Oct-4, SSEA-4, c-Myc), specific
MSCs markers (CD44, CD90, CD105, and CD146) and lack
expression of HLA-ABC, HLA1AG, and MHC II [12]. The low
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immunogenicity makes eUCM-MSCs ideal for cell therapy and
regenerative medicine applications, both for species-specific
purposes in equine medicine and as a large animal model of
pre-clinical trials. The horse is of particular interest in the
orthopaedic field, as bone, tendon and ligament diseases have a
significant impact on equine industry. Also, enhancing research
programs in this species could establish a particularly suitable
animal model useful for pre-clinical trials in humans. Infact,
current laboratory practices in equine regenerative medicine
mirror those in the human field. Morever, the translational use of
autologous and allogeneic MSCs for patient therapy far exceeds
what is currently permitted in human medicine [23]. To date,
stem cell therapy in equine orthopaedic diseases, a relatively new
research area, has been based mainly on the use of bone marrow
(BM-MSCs; [24,25]), adipose tissue (Ad-MSCs; [26]), amnion-
derived (AM-MSCs; [24]) and umbilical cord blood (UCB-MSCs;
[27]). The use of stem cells in equine neurological diseases/
neuropathies is still in a planning stage. The use of UCM-MSCs,
due to their particularly advantageous features, such as ease of
sourcing, high in vitro expandability and differentiation ability,
immune-evasion and immune-regulation capacities, high homing
ability, limited constraints due to ethical issues, low tumorigenicity,
and even tumoricidal ability [1,6,28,29] could allow significant
improvements of clinical therapeutical applications.
An important procedural aspect of stem cell-based therapies is
the control of proliferation and differentiation and extracellular
calcium ion (Ca2+) is known as a potent mediator of the balance
between proliferation and differentiation in a number of different
cell types [30,31]. The extracellular calcium-sensing receptor
(CaSR) is a G protein–coupled receptor able to bind extracellular
Ca2+ ions [32], firstly identified in bovine parathyroid cells by
Brown et al., [33], and subsequently involved in the regulation of
whole-body Ca2+ metabolism [30].
In this context, a large body of evidence supports a role of CaSR
in cell proliferation [31,34–41]. Indeed, a recent study from our
unit reported the CaSR is expressed in eUCM-MSCs and is
functionally active since calcium and the selective CaSR agonist
NPS R-467 stimulate cell growth/proliferation in these cell lines,
an effect which is reversed by the CaSR antagonist NPS2390 [13].
On the other hand, limited information is available on the role of
CaSR in cell differentiation. Indeed, studies reported to date
investigate its involvement in differentiation of specific lineages,
such as osteoblasts [42,43], osteoclasts [44], perinatal sympathetic
neurons [45], epidermal initiation sites in mouse developing
embryos and epidermic tissues [46] and preadipocytes [47]
whereas only few studies reported its role in driving/regulating
differentiation of embryonic [48] or fetal-derived stem cells ([49],
for amniotic fluid-derived stem cells). No studies are reported to
date on CaSR role in UCM-MSC differentiation.
Investigating whether CaSR affects ostegenic and neurogenic
differentiation potency of UCM-derived MSCs by means of its
selective agonists could contribute to elucidate differentiation
mechanisms and to optimize differentiation protocols and the
development of novel (even in utero and/or neonatal) targeted
therapies in both bone diseases and neurodegenerative disorders.
The aim of the present study was to investigate, in the horse as a
large animal model, the involvement of CaSR on osteogenic and
neurogenic differentiation potency of size-sieved UCM-MSC lines,
by testing the in vitro effects of AMG641, a novel research
calcimimetic acting as a CaSR agonist.
Materials and Methods
Chemicals
AMG641 (chemical name: (1R)-N- ((6-(methyloxy)-49-(trifluor-
omethyl)-3-biphenylyl)methyl)-1-phenylethanamine;) was provided
by Amgen Inc. (Thousand Oaks, California, USA; Research
Program Agreement nu 2011568566). NPS2390
(Quinoxaline-2-carboxilic acid adamantan-1-ylamide) was pur-
chased by Sigma (N4786), Milan Italy. NPS R-467 ((R)-N-(3-
phenylpropyl)-a-methyl-3-methoxybenzylamide hydrochloride)
was a kind gift of Dr. R. Caroppo (Dept. Biosciences, Biotech-
nologies and Biopharmaceutics, University of Bari, Italy)
Cell lines isolation and stemness molecular
charaterization
The study was carried out on two homogeneous subpopulations
of equine UCM-MSCs (eUCM-MSCs) [12,13]. Cells were isolated
from perivascular Wharton’s jelly by using a multi-dishes plate
with transwell inserts of 8 mm pores [12]. Therefore, we have
referred to the cells as size-sieved stem cells separated by their
dimension, one larger than 8mm (namely, large cell line) and the
other smaller than 8mm in diameter (namely, small cell line). The
two cell lines were molecularly characterized and found as
expressing CaSR at mRNA and protein level [13], pluripotency-
specific antigens (OCT-4 and c-Myc), MSC markers (CD105,
CD44, CD29 and CD166) and showing weak expression of
antigens TRA-1-60 and SSEA-4 and lack of expression of the
hematopoietic markers CD34, CD14 and MHC-II [12]. As well,
in these cell lines, cell growth significantly increased in presence of
high [Ca2+]o, (2.87 mM CaCl2), as previously reported [13].
Culture conditions
Cells were cultured at 38.5uC in a humidified atmosphere (95%)
under 5% CO2 in standard expansion medium, consisting of
Dulbecco’s Modified Eagle’s Medium - High Glucose (DMEM)
(Sigma D-5546) supplemented with 10% Fetal Calf Serum (FCS)
(Sigma F3018), 100 U/ml penicillin, 100 mg/ml streptomycin,
0.25 mg/ml amphoterycin solution (Sigma A-5955), 2 mM L-
glutamine (Sigma G-7513) and 10 ng/ml Epidermal Growth
Factor (EGF; Sigma E-9644).
Cell freezing
Standard medium supplemented with 10% (v/v) FCS and 10%
(v/v) dimethyl sulfoxide (DMSO, Sigma D-5879) was used to
cryopreserve cells in cryotubes that were stored at 280uC and
then transferred to cryogenic containers with liquid nitrogen until
molecular analysis.
Osteogenic and neurogenic differentiation induction
Osteogenic and neurogenic in vitro differentiation potential was
induced as previously reported [21,50]. Cells at P3 were seeded at
a density of 3000 cells /cm2 in six-well plates and were cultured
until they reached approximately 80–90% confluence. For
differentiation of MSCs into osteogenic lineage, cells were cultured
for 21 days in medium consisting of HG-DMEM, supplemented
with 10% FCS (Sigma), 100 U/ ml penicillin, 100mg/ml
streptomycin, 0.25mg/ml amphotericin B, 2 mM L-glutamine,
10 mM beta-glycerophosphate, 0.1 mM dexamethasone and
250 mM ascorbic acid. Neurogenic induction was performed by
culturing cells for 24 h in pre-induction medium consisting of HG-
DMEM, 20% FCS and 1 mM beta-mercaptoethanol, with neural
induction then performed by switching to a medium composed of
DMEM plus 2% FCS, 2% dimethylsulphoxide (DMSO) and
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200 mM butylated hydroxyanisole for 3 days. Non-induced
control cells (negative controls) were cultured for the same length
of time in standard medium (HG-DMEM supplemented with 10%
FCS, 100 U/ ml penicillin, 100 mg/ml streptomycin, 0.25mg/ml
amphotericin B, 2 mM L-glutamine).
Osteogenic differentiation assessment
Osteogenesis was assessed by alkaline phosphatase (ALP) assay
[51] and von Kossa staining [50] and by evaluating the relative
abundance of the transcripts of two osteogenic differentiation
markers, such as Runt-related transcription factor 2 (RUNX2) and
Osteopontin (OPN). Briefly, ALP activity, a typical osteoblast
marker, was assessed by using the Alkaline Phosphatase Kit (Sigma
Aldrich), a commercial kit based on naphthol AS-BI and fast red
violet LB [51]. After treatments in the conditions described below
(Experiment 2), cells were fixed with a citrate-acetone-formalde-
hyde fixative for 30 sec at room temperature. After being rinsed
with distilled water, cells were incubated for 15 min in dark with
alkaline-dye mixture (NaNO2, FRV-Alkaline Solution, Naphthol
AS-BI Alkaline Solution) and washed with distilled water. Cells
were counterstained with hematoxylin solution, washed in tap
water and evaluated under light microscopy. For von Kossa
staining, cells were washed with PBS and then fixed with 10%
formalin for 1 h at room temperature. The formalin was removed
and cells were washed with distilled water. A 5% (w/v) silver
nitrate solution was added and cells were exposed to UV light for
20 min. Reaction was stopped by using a 5% sodium thiosulphate
solution for 2 min. Cells were washed with distilled water.
Calcium phosphate deposits stained black [50].
Neurogenic differentiation assessment
Neurogenic differentiation was assessed by conventional Nissl
staining, beta III tubulin immunostaining and by evaluating the
relative abundance of the transcripts of the two neurogenic
differentiation markers, Glial Fibrillary Acidic Protein (GFAP) and
Nestin. Briefly, for Nissl staining, cells were washed with PBS and
then fixed with 10% formalin for 15 min at room temperature.
The formalin was removed and cells were washed with distilled
water and incubated in a 0.1% cresyl violet solution for 20 min.
Cells were washed with distilled water and observed under light
microscopy for the evaluation of Nissl bodies [50]. For beta III
tubulin, a specific neuronal marker, cells were seeded on cover
glass slides at the density of 1000 cell/cm2. After treatments in the
conditions described below (Experiment 2), cells were permeabi-
lized with 0.03% Triton X-100 for 15 min at room temperature
and then incubated for 10 min in 1% (w/v) Bovine Serum
Albumin (BSA) in PBS (PBS-BSA). After that, cells were incubated
overnight at room temperature with a 1:1000 dilution of a primary
rabbit polyclonal antibody against the beta III tubulin (ab18207;
Abcam, Cambridge, UK) in PBS-BSA. Cells incubated overnight
in PBS-BSA were used as negative (no primary antibody) controls.
At the end of incubation, cells were washed in PBS-BSA and
incubated for 2 h at room temperature with a fluorescein
isothiocyanate (FITC)- conjugated goat anti-rabbit IgG-secondary
antibody (ab6717, Abcam) diluted 1:500 in PBS-BSA. After
washing, cells were fixed in 2% para-formaldehyde solution in
PBS, mounted on slides and observed under oil immersion (630x
magnification) with a C1/TE2000-U Nikon confocal laser-
scanning microscope, equipped with an Argon Ions 488 laser
and an 495–519 (B2-A) nm excitation/emission filter.
Total RNA extraction
The RNeasy kit (QIAGEN, Milan, Italy) was used to extract
total RNA. After thawing, cells were washed in PBS and then
disrupted in Lysis Buffer RLT and homogenized at room
temperature. A 70% ethanol solution was then added to the
lysate, creating conditions that promoted selective binding of RNA
to the RNeasy membrane. The lysate was transferred to an
RNeasy spin column and centrifuged for 15 sec at 10000 rpm.
The column was washed twice with washing buffer and finally, the
total RNA was eluted in 30 ml of RNase-free water and stored at
280uC. The total amount of RNA of each sample was measured
using the BioPhotometer plus (Eppendorf, Milan, Italy).
Reverse Transcription PCR
The High Capacity cDNA Reverse Transcription kit (4368814,
LifeTechnologies, Monza, Italy) was used to convert RNA to
cDNA. After thawing, 1 mg of total RNA of each sample was
added to 2 mL 10X RT Buffer, 0.8 mL 25X dNTP Mix, 2 mL RT
Random Primers, 1 mL M-MLV Reverse Transcriptase,
1 mLRNase Inhibitor and nuclease-free water for a total volume
of 20 ml and then, the solution was mixed gently and centrifuged
briefly. Reaction tubes were incubated at 10uC for 10 min, then at
37uC for 120 min and finally at 85uC for 5 min. cDNA was stored
at 220uC until Real Time PCR analysis.
Real Time PCR
Real Time PCR was performed by using Real Time TaqMan
technology and analyzed on automated ‘‘StepOne System’’
(Applied Biosystem, Monza, Italy). All TaqMan equine primers
and probes were purchased from Life Technologies. Life
Technologies inventored gene assays were adopted for Hypoxan-
thine phosphoribosyltransferase 1 (HPRT1; Ec03470219_m1)
used as endogenous control, GFAP (Ec03470056_m1) and
RUNX2 (Ec03469741_m1). For the equine CaSR, OPN and
Nestin genes, primers and probes were specifically designed in the
present study across an exon-exon junction, using Primer Express
3.0 software (Applied Biosystem) based on NCBI Equus caballus
available nucleotidic sequences. The oligonucleotide sequences of
the above Real Time PCR primers and probes are shown in
Table 1. The TaqMan MGB (minor groove-binder) hybridization
probe was labeled with a reporter dye (6-carboxy-fluorescein,
FAM) on the 59 nucleotide and a quenching dye with NFQ (non
fluorescent quencher) on the 39 nucleotide where MGB hyper-
stabilized duplexes with complementary DNA. Samples were run
in duplicates on Microamp fast optical 48-well reaction plate (Life
Technologies) where twenty-microliters reactions for each well
contained: 10 mL TaqMan gene expression Master Mix 2X (Life
Technologies), 1mL 800 nM Primers and 250 nM Probe, 1–4 mL
cDNA and RNase Free H2O. Cycling parameters were: 2 min at
50uC, 10 min at 95uC followed by 40 cycles of 15 s at 95uC and
1 min at 60uC. Data were collected by using the StepOne
Software (Applied Biosystem, Monza, Italy) and relative quanti-
fication was performed by using comparative method after
determining the Ct (threshold cycle) values for the reference
endogenous control (HPRT1) and the target gene in each sample
sets, according to the 22DDCt method as described by the
manufacturer. Changes in mRNA expression levels were calcu-
lated after normalization to HPRT1. The program calculates
the DCt and the DDCt with the formulas below: DCt =
Ct_Mean(HPRT1) – Ct_Mean(target gene); DDCt = DCt –
DCt_Mean, so that the gene expression level = 22DDCt. Changes
in gene expression were reported as percentage changes relative to
controls.
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Experimental Design
Experiment 1: Effects of AMG641 on in vitro proliferation
of size-sieved eUCM-MSCs
To evaluate the optimal concentration of the calcimimetic, large
and small eUCM-MSCs cells were seeded in six well plates and
cultured in the standard medium supplemented with rising
concentrations of AMG641 (0.01, 0.05, 0.1, 0.5, 1 and 3 mM) in
presence of 2.5 mM CaCl2. Calcium concentration was selected
on the basis of a previous study from our unit [13] in which
2.5 mM CaCl2 was considered as CaSR EC50 in both cell lines.
External Ca2+ concentration ([Ca2+]o) in the present study, as in
our previous study by Martino et al., [13] was actually either 0.37
(low [Ca2+]o) or 2.37 mMCa
2+ (high [Ca2+]o). Infact, standard
medium was supplemented with 10% FCS and, since average
[Ca2+]o in FCS was around 1.6 mg/dL, thus 3.7 mM [52],
[Ca2+]o in our standard medium (10% FCS) was around
0.37 mM. When additional 2.5 mMCa2+ was included, final
[Ca2+]o was 2.87 mM (0.37+2.5 = 2.87 mM). Control cells were
cultured in medium with additional 2.5 mM CaCl2 in the absence
of AMG641. Negative controls were referred to cells cultured in
medium with low calcium concentration (0.37 mM CaCl2)
whereas positive controls were referred to values observed in cells
cultured in high calcium concentration and in presence of 3 mM
NPS R-467. For DT calculation, cells were seeded, at the density
of 1000 cell/cm2. The DT data were calculated by using the
following formula: CD = ln(Nf/Ni)/ln2 and DT = CT/CD,
where DT is the cell-doubling time, CD is the cell-doubling
number, CT is the cell culture time, Nf is the final number of cells
and Ni the initial number of cells. Cells of each well were detached
by using 0.05% trypsin/0.02% EDTA in PBS and were counted,
by dilution (1:1) in Trypan blue, with Burker9s counting chamber.
Cell counts were performed on days 4th after the beginning of the
treatments. Data were expressed as mean 6 standard deviation of
values obtained in three replicates. The Student’s t-test was used to
evaluate statistical significances and values with P,0.05 were
considered as statistically different.
Experiment 2: Effects of AMG641 on osteogenic and
neurogenic differentiation potential of eUCM-MSCs
Based on the results of experiment 1, three concentrations of
AMG641 (0.05, 0.1 and 1 mM AMG641), that were shown to
significantly stimulate cell proliferation, were selected to test its
effects on osteogenic (experiment 2a) and neurogenic (experiment
2b) differentiation potential of eUCM-MSCs.
Cells were cultured in following conditions: 1) control (CTRL):
osteogenic or neurogenic differentiation medium, as described
above; 2) high external calcium (2.5 mM CaCl2): differentiation
medium +2.5 mM CaCl2; 3) agonist (2.5 mM CaCl2+ AMG641):
differentiation medium plus 2.5 mMCaCl2 and AMG641 (0.05 or
0.1 or 1 mM); 4) antagonist/agonist (2.5 mM CaCl2 + NPS2390 +
AMG641): standard differentiation medium plus 2.5 mM CaCl2
and 1 mM AMG641. In these samples, before CaSR agonist
addition, cells were preincubated for 30 min with 10 mM
NPS2390. In both cell lines, after 14 days in vitro culture under
osteogenic differentiation induction conditions, ALP activity was
analyzed and, after 21 days, von Kossa staining was performed
and CaSR and osteogenic differentiation markers mRNA expres-
sion levels were evaluated. As well, in both cell lines, after 4 days of
neurogenic differentiation treatments, Nissl staining and beta III
tubulin immunostaining were performed and CaSR and neuro-
genic differentiation markers mRNA expression levels were
evaluated. The Student’s t-test was used to evaluate the statistical
significance of the results. Within each differentiation lineage,
differentiation biomarkers relative expression in the four above
mentioned treatments groups (CTRL, high calcium, agonist and
antagonist/agonist) were compared. ALP activity, extracellular
matrix mineralization (calcium deposits), Nissl bodies formation
and beta III tubulin immunostaining were quantified by densito-
metric analysis using Adobe Photoshop. For each experimental
condition, areas of constant size were measured. Staining intensity
was evaluated by recording: 1) the total stained area, 2) the
number of stained spots and 3) the mean spot area. Data (mean 6
standard deviation of values obtained in three replicates) were
expressed as number of pixels. The Student’s t-test was used to
evaluate statistical significances and values with P,0.05 were
considered as statistically different.
Results
Experiment 1: AMG641 stimulates in vitro proliferation of
eUCM-MSCs
In both cell lines, the proliferation rate was significantly
increased upon AMG641 treatment and the effects of this
compound were very similar between the two cell lines. In detail,
in the large cell line, AMG641 significantly reduced DT values
compared with controls (P,0.01 in cells treated with the two
lowest AMG641 concentrations, i.e. 0.01 and 0.05mM AMG641;
P,0.001 in cells treated with the four remaining higher AMG641
concentrations, i.e. 0.1, 0.5, 1 and 3 mM AMG641; Fig. 1, Panel
A). Likewise, in the small cell line, AMG641 significantly reduced
DT values compared with controls (P,0.05 in cells treated with
the two lowest AMG641 concentrations; P,0.001 in cells treated
with the remaining higher AMG641 concentrations; Fig. 1, Panel
B). In both cell lines, DT values in cells cultured in medium with
low calcium concentration (negative controls, CTRL) were
significantly higher than that of cell cultured in high calcium
(P,0.05). As well, in both cell types, DT values of cells cultured in
presence of 3 mM NPS R-467 (positive controls) were significantly
higher that those of 0.1 to 3 mM AMG641-treated cells (P,0.001
in both large and small cells), indicating a more sustained action of
AMG641 than NPS R-467. In both cell lines, treatment with
AMG641 had no effect on cell viability (Fig. 2; Panel A and Panel
B), indicating non toxic effect of this compound on these cell lines.
Table 1. Oligonucleotide sequences used for Real Time-PCR analysis.
Markers Forward Primer 59R 39 Reverse Primer 59R 39 Probe 59R 39
Calcium-Sensing Receptor (CaSR) CTTGGCAGGTCCTGAAGCA TGGTTGTTATACCCCCTGGTC CTACGGCACCTCAAC
Osteopontin (OPN) CGCAGATCTGAAGACCAGTATCCT TTGCTTTCCACAGGTGATGTG TGCTACGGAAGAGGAC
Nestin (Nes) ACTGAGAAGTTCCAGCTGGC GGACATCTTGAGGTGTGCCA GGGCCTGCAGAGCCAGATCGCCCAGG
doi:10.1371/journal.pone.0111533.t001
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Experiment 2a: CaSR activation promotes osteogenic
differentiation of eUCM-MSCs
Effects of AMG641 on bone-like cell morphology and
histochemical features. As a first approach to evaluate the
effects of higher Ca2+ on AMG641 action on osteogenic
differentiation potency of eUCM-MSCs lines, cell morphology,
cytochemical and histochemical characteristics were analyzed.
Cells were evaluated at P3. In both cell lines, ALP positivity was
found in cells induced to differentiate through the osteogenic
lineage with significantly higher proportions of ALP+ cells after
treatment with high [Ca2+]o plus AMG641 compared with high
[Ca2+]o alone (P,0.05 and P,0.01 for the large and the small cell
lines, respectively). As well, in both cell lines, the CaSR antagonist
NPS2390 reversed the stimulatory effect of AMG641 (P,0.01;
Fig. 3, panel A, B). ALP quantification analysis confirmed these
observations, as significantly higher ALP activity was found in
AMG641-treated cells compared with high [Ca2+]o alone controls
(P,0.05) and this effect was reversed by addition of NPS2390 (P,
0.05; Fig. 3, panel C, D). Figures 4 and 5 show representative
photomicrographs of ALP and von Kossa stained cells in both
large and small cell lines, respectively. Clearly evident ALP
positivity and conspicuous mineralized extracellular matrix
deposition by von Kossa staining with no apparent differences
among those cultured in presence of low (Fig. 4 A, F) or high
[Ca2+]o (Fig. 4 B, G) or high [Ca
2+]o plus AMG641 (Fig. 4 C, H)
were observed. Instead, in cells pre-incubated with the CaSR
antagonist NPS2390 and subsequently treated with AMG641,
reduced proportion of ALP+ cells and reduced amount of calcium
phosphate deposits were observed (Fig. 4 D, I). Non-induced
negative control cell lines showed neither ALP positivity nor
relevant calcium phosphate deposits after von Kossa staining
(Fig. 4 E, L). These observations can be similarly referred to the
large, as well as to the small cell line (Fig. 5 A to L). Quantification
Figure 1. Effects of the calcimimetic AMG641 on in vitro proliferation of size-sieved eUCM-MSC lines. Cells were plated in 6-wells plates
and treated as described in materials and methods. The effects of increasing doses of AMG641 in presence of 2.5 mM extracellular Ca2+ on the large
(Panel A) and the small (Panel B) eUCM-MSC cell line are shown. In both cell lines, AMG641 significantly increased cell proliferation, expressed as
significantly reduced doubling time (DT) values. DT values in cells cultured in medium with low calcium concentration (negative controls, CTRL) were
significantly higher than those of cell cultured in high calcium (0 mM AMG641). DT values of cells cultured in presence of NPS R-467 (3mM, positive
controls) were significantly higher that those of AMG641-treated cells. Data are mean 6 standard deviation of values obtained in three replicates.
Student’s t-test: comparisons AMG641-treated cells vs controls (low and high calcium) and among used AMG641 concentrations: *P,0.05; **P,0.01;
***P,0.001; comparisons AMG641- vs NPS R-467-treated cells: uP,0.01; uuP,0.001.
doi:10.1371/journal.pone.0111533.g001
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analysis of von Kossa stained specimens allowed to observe that
cells induced to osteogenic differentiation showed significantly
higher mineralization level in response to CaSR activation by the
calcimimetic AMG641 (comparison 1 mM AMG641-treated cells
vs high high [Ca2+]o control: P,0.05 in large cells, Fig. 6, Panel A;
P,0.001 in small cells, Fig. 6, Panel B). The addition of the CaSR
antagonist NPS2390 significantly reversed the agonists effects (P,
0.001 in both large and small cells).
Effects of high [Ca2+]o on CaSR and osteogenic
biomarkers expression. Elevating [Ca2+]o in culture medium
during osteogenic differentiation significantly increased the relative
abundance of osteogenic differentiation biomarkers compared
with that observed in standard differentiation conditions (CTRL).
In the large cell line, additional Ca2+ up-regulated Osteopontin
(OPN, P,0.05) and CaSR (P,0.05) mRNA expression even if it
had no effect on relative expression of the Runt-related
transcription factor, RUNX2 (Fig. 7, Panel A) whereas in the
small cell line, high [Ca2+]o significantly increased both OPN and
RUNX2 transcripts level (P,0.001 and P,0.01, respectively;
Fig. 7, Panel B) but it had no effects on CaSR expression.
Effects of AMG641 on CaSR and osteogenic biomarkers
expression. The addition of AMG641 in presence of high
[Ca2+]o during osteogenic differentiation induced opposite effects
in the two cell lines. In the large cell line, AMG641 increased OPN
transcription (P,0.05 and P,0.01 with 0.1 and 1 mM AMG641,
respectively) and had no effect on RUNX2 expression (Fig. 8,
Panel A) while, conversely, in the small cell line, AMG641
significantly down-regulated OPN (P,0.05, P,0.01 and P,0.05
in cells stimulated with 0.05, 0.1 and 1 mM AMG641, respectively)
and RUNX2 transcription (P,0.05 in cells treated with 0.1 mM
AMG641) (Fig. 8, Panel B). Interestingly, CaSR transcription was
found to be inversely related to the expression of osteogenic
markers. In fact, it was significantly down-regulated in the large
cell line (P,0.01 at 0.05 and 0.1 mM AMG641), but markedly up-
regulated in the small cell line, with a clear dose-response effect
(P,0.05, P,0.01 and P,0.0001, at 0.05, 0.1 and 1 mM
AMG641, respectively). In both cell lines, the addition of
NPS2390 reversed the effects of the CaSR agonist AMG641 on
OPN mRNA levels, with significant down-regulation in large cells
(P,0.01) and up-regulation in small cells (P,0.001) whereas it had
no effects on RUNX2 mRNA levels. In both cell lines, NPS2390
Figure 2. Effects of the calcimimetic AMG641 on cell viability of size-sieved eUCM-MSC lines. Cell viability is expressed as percentage of
living (unstained) cells after Trypan blue staining. The effects of increasing doses of AMG641 in presence of 2.5 mM extracellular Ca2+ on the large
(Panel A) and the small (Panel B) eUCM-MSC cell line are shown. Cell viability remained at high values, indicating non toxic effects of AMG641 on
these cell lines. As in Figure 1, values in cells cultured in medium with low calcium concentration are referred as negative controls (CTRL) and values
observed in cells cultured in presence of 3 mM NPS R-467 are referred as positive controls (R-467). Data are mean 6 standard deviation of values
obtained in three replicates. Student’s t-test: NS.
doi:10.1371/journal.pone.0111533.g002
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was not able to reverse the effect of AMG641 on CaSR relative
abundance.
Experiment 2b: CaSR activation promotes neurogenic
differentiation of eUCM-MSCs
Effects of AMG641 on neuron-like cell morphology. The
effects of AMG641 in presence of additional Ca2+ on neurogenic
differentiation potency of eUCM-MSC lines, were assessed by cell
morphology and cytochemical characteristics. Cells were evaluat-
ed at P3. Cells directed toward neurogenic differentiation showed
diffused discrete granular bodies after Nissl staining, with no
apparent differences among those cultured in presence of low
(Fig. 4 M) or high [Ca2+]o (Fig. 4 N) or high [Ca
2+]o plus
AMG641 (Fig. 4 O) or in cells pre-incubated with the CaSR
antagonist NPS2390 and subsequently treated with AMG641
(Fig. 4 P). A low percentage of cells (around 1%) became more
elongated and showed neuronal-like morphology, as they
displayed beta III tubulin immunopositivity throughout the cell
body, the axon and dendritic-like extensions (Fig. 4 R,S,T,U).
Non-induced negative controls showed neither Nissl nor beta III
tubulin labeling (Fig. 4 Q, V). These observations can be similarly
referred to the small cell line (Fig. 5 M to V). In both cell lines,
densitometric analysis for Nissl bodies quantification did not show
statistically significant differences among groups (Fig.6, Panel C
and Panel D). Densitometric analysis of beta III tubulin labeled
cells did not reveal statistical differences among groups (data not
shown).
Effects of high [Ca2+]o on CaSR and neurogenic
biomarkers expression. In both cell lines, additional Ca2+
up-regulated Nestin (P,0.05 in the large cell line, Fig. 7, Panel C;
P,0.01 in the small cell line, Fig. 7, Panel D) and CaSR (P,0.05
in both cell lines) mRNA expression whereas the GFAP transcript
was never detected in any examined culture condition.
Effects of AMG641 on CaSR and neurogenic biomarkers
expression. The addition of AMG641 during neurogenic
differentiation induced similar effects in the two cell lines. In
detail, in both cell lines, it significantly increased Nestin mRNA
level when added at 1 mM (P,0.05; Fig. 8 Panels C and D). The
GFAP transcript was never detected in both cell lines, either
cultured with or without AMG641. As well, in both cell lines, the
treatment with AMG641 significantly increased the CaSR
transcript level (P,0.05 and P,0.001 at 0.05 and 1 mM
AMG641 respectively in the large cell line; Fig. 8, Panel C and
P,0.05 an P,0.001 at 0.05 and 0.1 mM AMG641, respectively in
Figure 3. Effects of calcium and the calcimimetic AMG641 on osteogenic differentiation efficiency of size-sieved eUCM-MSC lines,
as assessed by ALP activity. Panel A: percentages of ALP+ cells in the large and small cell lines observed after treatments, as described in M&M,
Experiment 2: (CTRL) control cells differentiated in vitro in presence of low [Ca2+]o; (0) cells differentiated in vitro in presence of high [Ca
2+]o; (1)
AMG641-treated cells (treated with 1 mM AMG641 in presence of of high [Ca2+]o); (NPS2390+1) NPS2390/AMG641-treated cells (cells pre-incubated
for 10 min in 10 mM NPS2390 and then cultured in 1 mM AMG641in presence of of high [Ca2+]o). A minimum of 500 cells per experimental condition
was counted. In both cell lines, the addition of AMG641 significantly increased the proportion of ALP+ cells (1 vs 0: P,0.05 and P,0.01 for large and
small cell lines, respectively). As well, in both cell lines, the CaSR antagonist reversed the stimulatory effect of AMG641 on ALP activity (P,0.01). Panel
B: Quantification analysis was performed by measuring the total stained area normalized on the number of counted cells. Data are expressed as
number of pixels. Significantly higher ALP activity was found after AMG641 treatment (1 vs 0: P,0.05) and significantly lower ALP activity was found
after antagonist treatment compared with AMG641 (NPS2390+1 vs 1: P,0.05). Non-induced controls (non induced to differentiate in vitro) showed 0
value in both cell lines and in both panels, as ALP positivity was not observed at all in these samples (data not shown).
doi:10.1371/journal.pone.0111533.g003
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Figure 4. Bone-like and neuron-like morphology, cytochemical and histochemical features of AMG641-treated large eUCM-MSCs as
evaluated by ALP activity, von Kossa and Nissl stainings and beta III tubulin immunodetection. Photomicrographs representative of the
morphological appearance of the large eUCM-MSC line induced to differentiate in vitro toward osteogenic (1st and 2nd column) or neurogenic (3rd
and 44h column) lineages in presence of 1mM AMG641 and observed after ALP activity assay, von Kossa and Nissl stainings, and beta III tubulin
immunostaining. (A, F, M, R) control cells differentiated in vitro in presence of low [Ca2+]o; (B, G, N, S) cells differentiated in vitro in presence of high
[Ca2+]o; (C, H, O, T) AMG641-treated cells (treated with 1 mM AMG641 in presence of of high [Ca
2+]o); (D, I, P, U) NPS2390/AMG641-treated cells (cells
pre-incubated for 10 min in 10 mM NPS2390 and then cultured in 1 mM AMG641in presence of of high [Ca2+]o); (E, L, Q, V) non-induced controls.
Osteogenic differentiation was evidenced by increased ALP activity observed after 14 days in vitro culture and by the formation of mineralized matrix
as shown by von Kossa staining after 21 days in vitro culture. No apparent differences can be seen for ALP activity and for the presence of mineral
deposits after treatment with high [Ca2+]o (B, G) or with AMG641 in high [Ca
2+]o (C, H) compared with controls (CTRL: A, F). ALP positivity and amount
of calcium phosphate deposits appear to be reduced in antagonist/agonist-treated cells (D, I) compared with those treated with the CaSR agonist
AMG641 (C, H). Neurogenic differentiation was evidenced by the presence of Nissl bodies and beta III tubulin positivity, as observed after 4 days in
vitro culture. All cells directed toward neurogenic differentiation showed diffused discrete granular bodies after Nissl staining with no apparent
differences among those cultured in presence of low (M) or high [Ca2+]o (N) or high [Ca
2+]o plus AMG641 (O) or in cells pre-incubated with the CaSR
antagonist NPS2390 and subsequently treated with AMG641 (P). Some cells showed neuron-like appearance and pancytoplasmic beta III tubulin
immunopositivity in all induced conditions (R,S,T, U) with no apparent differences among treatments. Non-induced control cells were unstained for
osteogenic (E, L) and neurogenic (Q, V) markers. Black scale bars indicate 10 mm; white scale bars indicate 5 mm.
doi:10.1371/journal.pone.0111533.g004
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Figure 5. Bone-like and neuron-like morphology, cytochemical and histochemical features of AMG641-treated small eUCM-MSCs
as evaluated by ALP activity, von Kossa and Nissl stainings and beta III tubulin immunodetection. Photomicrographs representative of
morphological appearance of the small eUCM-MSC line induced to differentiate in vitro toward osteogenic (1st and 2nd column) or neurogenic (3rd
and 44h column) lineages in presence of 1mM AMG641 and observed after ALP activity assay, von Kossa and Nissl stainings, and beta III tubulin
immunostaining. As in Figure 4, control cells differentiated in vitro in the presence of low [Ca2+]o (A, F, M, R), cells differentiated in vitro in the
presence of high [Ca2+]o (B, G, N, S), AMG641-treated cells (treated with 1 mM AMG641 in the presence of high [Ca
2+]o) (C, H, O, T), NPS2390/AMG641-
treated cells (cells pre-incubated for 10 min in 10 mM NPS2390 and then cultured in 1 mM AMG641in the presence of high [Ca2+]o) (D, I, P, U) and
non-induced controls (E, L, Q, V) are shown. As in the large cells, no apparent differences can be seen for ALP activity and for the presence of mineral
deposits after treatment with high [Ca2+]o (B, G) or with AMG641 in high [Ca
2+]o (C, H) compared with controls (CTRL: A, F). Even in small cells, ALP
positivity and the amount of calcium phosphate deposits appears to be significantly reduced in antagonist/agonist-treated cells (D, I) compared with
those treated with the CaSR agonist AMG641 (C, H). All cells directed toward neurogenic differentiation showed discrete granular bodies after Nissl
staining no apparent differences among those cultured in presence of low (M) or high [Ca2+]o (N) or high [Ca
2+]o plus AMG641 (O) or in cells pre-
incubated with the CaSR antagonist NPS2390 and subsequently treated with AMG641 (P) can be seen. Some cells showed neuron-like appearance as
they displayed beta III tubulin immunopositivity throughout the cell body, the axon and dendritic-like extensions with no apparent differences
among treatments. Non-induced control cells were unstained for osteogenic (E, L) and neurogenic (Q, V) markers. Black scale bars indicate 10 mm;
white scale bars indicate 5 mm.
doi:10.1371/journal.pone.0111533.g005
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the small cell line; Fig. 8, Panel D). No repeatable reverse effects
were obtained upon NPS2390 addition.
Discussion
The proliferation study was performed with the aim to
preliminary testing in vitro AMG641 activity on equine fetal
adnexa-derived size-sieved UCM-MSCs. A dose-response effect of
AMG641 on the proliferation rate of eUCM-MSCs was observed.
AMG641 in presence of high [Ca2+]o significantly increased cell
proliferation in both large and small eUCM-MSCs lines. To the
best of our knowledge, this is the first study on the effects of
AMG641 on cell proliferation of in vitro cultured cell lines and,
more specifically, in fetal-adnexa derived mesenchymal stem cell
lines. AMG641 is a research calcimimetic mainly reported to date
in studies on calcium homeostasis disorders [54–57]. Recent
studies reported its effect as selective activator of CaSR [55,58–
61]. Only one study has been reported to date, on the effects of
AMG641 on in vivo cell proliferation [58] and reduced or
unchanged proliferation rates were observed in cells obtained from
parathyroid tissues of five-sixth nephrectomized rats, after the
application of a long or short term in vivo administration protocol
of AMG641, respectively. Our data cannot be easily compared
with those of the study by Mendoza et al., [58], due to different in
vivo versus in vitro adopted experimental approaches. Moreover,
AMG641 has been reported as having different effects attending to
cell types [60]. Further comparisons can be performed with
previous studies reporting the effects of other selective CaSR
agonists on the proliferation of fetal-adnexa derived MSCs. Our
group reported that NPS R-467 stimulates cell proliferation in the
same cell lines, eUCM-MSCs [13]. Interestingly, the stimulatory
effect of AMG641 on cell proliferation was evident even at the
very low tested concentrations (0.01 mM) whereas higher concen-
trations of NPS R-467 (3mM; [13,38]) or its precursor NPS R-568
(0.3–1 mM; [35]) were reported in previous studies. The stimula-
tory effect of NPS R-467 was confirmed in the present
proliferation study, as it was used as positive control. This finding
could be considered of high importance for the use of this novel
potent calcimimetic as a component of media for fetal-derived
MSC cultures, in protocols aimed to obtain enough cells for
downstream purposes of cell therapy applications.
Given that it was previously demonstrated that physiological
changes in [Ca2+]o control, via CaSR, the fate of progenitor cells
of specific lineages (such as osteogenic, neurogenic, adipogenic and
epidermic lineages: see Introduction for references) toward their
specific differentiation routes, after testing the dose-response effect
Figure 6. Effects of calcium and the calcimimetic AMG641 on osteogenic and neurogenic differentiation efficiency of size-sieved
eUCM-MSC lines, as assessed by quantification of extracellular matrix mineralization and Nissl bodies formation. Densitometric
analysis was performed in large and small cells after von Kossa (Panel A and B) and Nissl staining (Panel C and D). For each experimental condition,
areas of constant size were measured. Staining intensity was evaluated by recording: 1) the total stained area, 2) the number of stained spots and 3)
the mean spot area. Data (mean 6 standard deviation of values obtained in three replicates) are expressed as number of pixels. Cells induced to
osteogenic differentiation showed higher mineralization levels in response to CaSR activation by the calcimimetic AMG641 (large and small cells). The
addition of the CaSR antagonist NPS2390 reversed the agonists effects. In both cell lines, no statistical differences were noticed among treatments for
Nissl staining intensity values. Student’s t-test: comparisons AMG641-treated cells vs controls (low and high calcium) and among used AMG641
concentrations: *P,0.05; **P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0111533.g006
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of AMG641 on cell proliferation, we wanted to test the effects of
this potent research calcimimetic on the differentiation potency of
fetal mesenchymal stem cell populations, such as UCM-MSCs,
considered as less committed and having wider stemness
bounderies than progenitor cells of specific lineages.
In UCM-MSCs, we showed that keeping elevated [Ca2+]o in
culture medium during osteogenic differentiation induced over-
expression of bone differentiation-related genes. The observed cell
responses had different extent in the two examined cell lines. In
detail, in the large cell line, high [Ca2+]o up-regulated OPN
mRNA expression, whereas in the small cell line it increased both
OPN and RUNX2 mRNA levels. These results may be
interpreted in light of different roles played by these osteogenic
biomarkers. Indeed, RUNX2 (also known as Core binding factor
alfa 1, Cbfa 1) is the master osteoblast transcription factor
responsible for osteoblast differentiation and mineralization
whereas OPN is a major osteoblast organic matrix protein
downstream of RUNX2 [42]. Thus, it could be possible that in
the small cell line (less committed), high [Ca2+]o was able to up-
regulate the master gene RUNX2 and, consequently, its down-
stream gene OPN. Whereas, in the large cell line (more
committed), high [Ca2+]o was only able to stimulate OPN
expression. These findings are in part in agreement with studies
published meanwhile our study was performed [49,62]. In human
bone marrow mesenchymal stromal cells cultured in vitro,
elevated [Ca2+]o was reported to induce over-expression of genes
coding for bone-related extracellular matrix proteins, such as
OPN, Osteocalcin and bone sialoprotein but it had no effects on
RUNX2 [62]. In the same study, the authors reported evidences
demonstrating that the signaling pathway between extracellular
Ca2+and bone morphogenetic protein 2 (BMP-2), a protein
essential to maintain bone homeostasis and having a prominent
role in fracture healing, involves type L voltage-dependent
Ca2+channels (L-VDCC) rather/more than CaSR. A subsequent
study strengthen the role of CaSR in supporting osteogenic
differentiation, as it demonstrated that extracellular calcium
promotes osteogenic differentiation in human periodontal liga-
ment stem/progenitor cells and that CaSR and L-VDCC appear
Figure 7. Relative abundance of CaSR and specific osteogenic and neurogenic differentiation biomarkers in eUCM-MSCs upon
Ca2+–induced CaSR stimulation. Panels A, B: Quantitative Real Time RT-PCR analysis of CaSR, OPN and RUNX2 transcripts in high [Ca2+]o-treated
equine UCM-MSCs (2.5 mM CaCl2) versus low [Ca
2+]o controls (CTRL). In the large cell line, additional Ca
2+ up-regulated CaSR (P,0.05) and OPN (P,
0.05) mRNA expression even if it had no effect on RUNX2 (Panel A). In the small cell line, high [Ca2+]o significantly increased both OPN and RUNX2
transcripts level (P,0.001 and P,0.01, respectively; Panel B) but it had no effects on CaSR expression. Panels C, D: Quantitative Real Time RT-PCR
analysis of CaSR, Nestin and GFAP transcripts in high [Ca2+]o-treated equine UCM-MSCs (2.5 mM CaCl2) versus low [Ca
2+]ocontrols (CTRL). In both cell
lines, additional Ca2+ up-regulated Nestin (P,0.05 in the large cell line, Panel C; P,0.01 in the small cell line, Panel D) and CaSR (P,0.05) mRNA
expression whereas the GFAP transcript was not detected. For each sample, average Ct data (mean6SD of three independent experiments in
duplicate) were normalized relatively to the abundance of HPRT1 mRNA (endogenous control) and normalized values were compared between
groups. Student’s t-Test; *P,0.05; **P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0111533.g007
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to act reciprocally in mediating this process [63]. In ovine amniotic
fluid MSCs, increasing [Ca2+]o was reported to increase ALP
activity [49]. Our data allow to confirm that Ca2+ is a potential
osteo-inductive triggerer in UCM-MSCs, and that observed
difference in the RUNX2 expression between the two cell lines
tested in the present study could be related to differences in their
developmental and functional stage (commitment level), as
previously reported [12,13]. Similarly, Ca2+-induced up-regulation
of osteogenic biomarkers was associated with up-regulation of
CaSR expression (significant increase in the large cell line and
increasing trend in the small cell line), leading us to hypothesize
that Ca2+-induced stimulation of osteogenic differentiation could
be mediated by CaSR.
The addition of AMG641 during osteogenic differentiation
induced opposite effects in the two cell line types. In fact, in the
large cell line, AMG641 promoted osteogenic differentiation as it
significantly increased OPN transcription, ALP activity and cell
mineralization level even if it had no effect on RUNX2 expression,
as observed in the same cell line upon stimulation with high
[Ca2+]o. Conversely, in the small cell line, AMG641 significantly
down-regulated OPN and RUNX2 transcription even though it
significantly increased ALP activity and calcium phosphate deposit
formation. This apparent discrepancy may be explained consid-
ering that the formation of the organic glycoproteic and inorganic
mineralized extracellular matrix are distinct events in the sequence
leading to bone formation. Mineralization is regulated by a
Figure 8. Relative abundance of CaSR and specific osteogenic and neurogenic differentiation biomarkers in eUCM-MSCs upon
calcimimetic AMG641-induced CaSR stimulation. Panels A, B: Quantitative Real Time RT-PCR analysis of CaSR, OPN and RUNX2 transcripts
inhigh [Ca2+]o and (0.05, 0.1 or 1 mM) calcimimetic AMG641-treated equine UCM-MSCs (2.5 mM CaCl2+AMG641) or cells pre-incubated with the CaSR
antagonist NPS2390 (2.5 mM CaCl2+NPS2390+AMG641) versus cells cultured in high [Ca2+]o (2.5 mM CaCl2) alone (indicated as 0 mM AMG641). In the
large cell line, AMG641 increased OPN transcription (P,0.05 and P,0.01 with 0.1 and 1 mM AMG641, respectively) and had no effect on RUNX2
expression (Panel A). In the small cell line, AMG641 significantly down-regulated OPN (P,0.05, P,0.01 and P,0.05 respectively in cells stimulated
with 0.05, 0.1 and 1 mM AMG641) and RUNX2 transcription (P,0.05 in cells treated with 0.1 mM AMG641) (Panel B). Upon AMG641 addition, CaSR
expression was significantly down-regulated in the large cell line (P,0.01 at 0.05 and 0.1 mM AMG641), but markedly up-regulated (up to
approximately 9 folds) in the small cell line, with a dose-response effect (P,0.05, P,0.01 and P,0.0001, at 0.05, 0.1 and 1 mM AMG641, respectively).
In both cell lines, the addion of NPS2390 reversed the effects of AMG641 on OPN mRNA levels, with significant reduction in large cells (P,0.01) and
significant increase in small cells (P,0.001) whereas it had no effects on RUNX2 mRNA levels. In both cell lines, the CaSR relative abundance remained
at comparable levels after agonist or antagonist/agonist treatments. Panels C, D: Quantitative Real Time RT-PCR analysis of CaSR, Nestin and GFAP
transcripts in cells cultured in the conditions as described for Panels A,B. In both cell lines, AMG641 significantly increased Nestin mRNA level at the
highest tested dose (1 mM, P,0.05; Panels C and D). The GFAP transcript was never detected in any examined condition (not shown). As well, in both
cell lines, AMG641 significantly increased CaSR transcription level (up to six folds in the large cell line; P,0.05 and P,0.001 at 0.05 and 1 mM AMG641
respectively; Panel C and up to approximately 4 folds in the small cell line; P,0.05 an P,0.001 at 0.05 and 0.1 mM AMG641, respectively; Panel D). In
both cell line types, no repeatable reverse effects were obtained upon NPS2390 addition (data not shown). For each sample, average Ct data
(mean6SD of three independent experiments in duplicate) were normalized relatively to the abundance of HPRT1 mRNA (endogenous control) and
normalized values were compared among groups. Student’s t-Test: a,b P,0.05; c,d P,0.01; e,f P,0.001; * P,0.01; ** P,0.001.
doi:10.1371/journal.pone.0111533.g008
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complex arrangement of stimulatory and inhibitory components
[42] and AMG641-mediated CaSR stimulation may result in a
balance between stimulatory and inhibitory factors involved in
calcium phosphate crystal formation and prevention of eccessive
mineralization. Our data on the effects of CaSR stimulation on
osteogenic differentiation can be compared with those of the
recently published study by Di Tomo et al., [49] who reported that
the addition of the calcimimetic R-568, a selective CaSR agonist,
in ovine amniotic fluid MSCs, increases cell mineralization (as
expressed by ALP and Alizarin red S) and this effect is reversed by
Calhex 231, a CaSR allosteric inhibitor. The same group
confirmed these results in human amniotic fluid MSCs [53].
Our data allow us to confirm that CaSR is involved in the
osteogenic differentiation of UCM-MSC because the research
calcimimetic AMG641 used in the present study is a selective
CaSR activator [59,60]. The different molecular cell responses
observed in large and small cell lines, may be due to their different
developmental and functional maturity (different commitment
status, as discussed above), including possible differences in the
CaSR gene structure, gene expression regulatory mechanisms or
signal transduction pathways, as previously hypothesized by
Martino et al, [13]. Interestingly, and unlike observed stimulation
with high [Ca2+]o, the calcimimetic AMG641-induced regulation
of osteogenic biomarkers expression was inversely related to that of
CaSR transcript, which was significant down-regulated in the
large cell line where osteogenic differentiation was promoted, but
markedly up-regulated in the small cell line, where osteogenesis
was inhibited. This finding is not in agreement with the R-568-
induced significant incresase of CaSR protein expression reported
by Di Tomo et al., [49] in ovine amniotic fluid MSCs. These
differences may be due to differences in the two calcimimetics
action mechanisms, probably eliciting different signaling path-
ways, and/or to differences in the commitment status of analyzed
cell lines. As a further confirmation to the observed CaSR-
mediated effect on eUCM-MSC, we tried to revert the effect
observed in the presence of AMG641 by using a CaSR antagonist,
NPS2390. As previously observed, NPS2390 is a potent and
selective non-competitive group I metabotropic glutamate recep-
tor (mGluR) antagonist [64]. In relation to CaSR’s reported high
structural homology with mGluR1 [65], NPS2390 has been used
as CaSR antagonist in previous studies [13,66–68]. Indeed, in the
present study, NPS2390 reversed the effects of AMG641 on OPN
mRNA transcription levels, which were down-regulated in the
large cell line and up regulated in the small cell line. As well, in
both cell lines it significantly reversed the AMG641-induced effect
on ALP activity and calcium phosphate deposit formation. Taken
together, our data allowed us to demonstrate that AMG641
significantly enhanced osteogenic differentiation efficiency in
equine UCM-MSCs. All these findings suggest that Ca2+ and
the calcimimetic AMG641 promote osteogenic differentiation via
CaSR. However, differences in synergic (Ca2+) or inverse
(AMG641) regulation of CaSR and osteogenic markers mRNA
levels, lead us to hypothesize that these two agonists may act
through different pathways.
Concerning neurogenic differentiation, we also showed that
keeping elevated [Ca2+]o, during differentiation culture resulted in
the over-expression of a specific gene involved in neurogenesis.
Indeed, in both cell lines (even with different significance levels in
the two cell types), we found over-expression of the gene coding for
Nestin, which is an intermediate filament protein associated with
immaturity in the nervous system [69]. Nestin has been reported
as a prerequisite for the acquisition of the capacity to progress
towards the neural lineage [69] and also as a neuronal stem cells
marker implied in neuronal differentiation of MSCs [70,71].
Moreover, expression of GFAP was never found in our trials,
indicating that culture conditions examined in the present study
are not useful to walk the differentiation road leading to the
development of mature astrocytes [69]. These findings are in line
with those of a previous study by Vizard et al., [45] in which it was
reported that the effects of increased [Ca2+]o in mouse late fetal
sympathetic neurons in culture enhances axonal growth, thus
showing that calcium is involved in the regulation of the growth of
neural processes in the central and peripheral nervous system.
The addition of AMG641 during neurogenic differentiation
increased CaSR and Nestin mRNA expression in both the large
and the small cell line. Our observations of a synergic up-
regulation of CaSR and the neurogenic biomarker Nestin mRNA
levels, by both CaSR agonists (Ca2+and AMG641) and in both cell
lines, even associated with non quantitatively relevant effects on
Nissl bodies formation and beta III tubulin immunopositivity,
support our hypothesis that CaSR is involved in early-stage
neurogenic differentiation of UCM-MSCs, as reported in previous
studies in other cell systems [72]. The stimulatory effects of the
CaSR agonist observed in our study are also in line with those
reported by Vizard et al., [45] who showed that activating CaSR
in perinatal sympathetic neurons with the calcimimetic NPS R-
467 enhances axonal and dendritic growth in culture and this
effect is reversed by the selective CaSR antagonist NPS89636 and
cannot be obtained in CaSR deficient mice. Nevertheless, the
study by Vizard et al. was performed on perinatal neurons [45].
Lack of reproducible reversion effects by NPS2390 on the
analyzed neurogenic differentiation biomarkers (Nissl bodies
formation and Nestin mRNA levels) was observed. However, the
possibility that NPS2390 could reverse expression or activity of
other CaSR-induced neurogenic differentiation biomarkers cannot
be excluded.
In conclusion, this study demonstrates that CaSR stimulation,
by means of the calcimimetic AMG641 in presence of high
[Ca2+]o, increases cell proliferation and increases osteogenic
differentiation efficiency and early-stage neurogenic differentiation
in UCM-MSCs, a unique fetal adnexa-derived MSC family with
components presenting various stemness degree, thus a unique
versatile opportunity in future cell therapy strategies. Moreover,
our findings showed that CaSR activation may play a fundamental
role in selecting specific differentiation checkpoints of these two
differentiation routes, as related to cell commitment status,
including differences in CaSR gene and/or protein structure
and/or function, and used agonists. This CaSR-mediated selection
of specific differentiation checkpoints could be of considerable
utility in future therapeutical applications. Lastly, our data open
the way to the use of the calcimimetic AMG641 in bone and
nervous system regenerative medicine.
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